$1.56
2.20% today
Nasdaq, Apr 04, 09:17 pm CET
ISIN
US45773H2013
Symbol
INO

Inovio Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation

Inovio Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
50%
Hold
50%

Inovio Pharmaceuticals, Inc. Price Target

Target Price $7.83
Price $1.59
Potential
Number of Estimates 6
6 Analysts have issued a price target Inovio Pharmaceuticals, Inc. 2026 . The average Inovio Pharmaceuticals, Inc. target price is $7.83. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 6 analysts: 3 Analysts recommend Inovio Pharmaceuticals, Inc. to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Inovio Pharmaceuticals, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Inovio Pharmaceuticals, Inc. stock at Buy or hold.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 0.22 2.57
73.49% 1,066.00%
Net Margin -64,815.91% -1,351.02%
144.70% 97.92%

6 Analysts have issued a sales forecast Inovio Pharmaceuticals, Inc. 2025 . The average Inovio Pharmaceuticals, Inc. sales estimate is

$2.6m
Unlock
. This is
1,066.00% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$15.2m 6,805.00%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $220k 73.49%
2025
$2.6m 1,066.00%
Unlock
2026
$21.6m 742.02%
Unlock
2027
$64.8m 200.14%
Unlock
2028
$165m 153.80%
Unlock
2029
$310m 88.25%
Unlock

1 Analyst has issued a net profit forecast Inovio Pharmaceuticals, Inc. 2025 . The average Inovio Pharmaceuticals, Inc. net profit estimate is

$-34.7m
Unlock
. This is
75.88% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-34.7m 75.88%
Unlock
, the lowest is
$-34.7m 75.88%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-143m 35.14%
2025
$-34.7m 75.69%
Unlock
2026
$-19.9m 42.70%
Unlock
2027
$-5.4m 72.71%
Unlock

Net Margin

2024 -64,815.91% 144.70%
2025
-1,351.02% 97.92%
Unlock
2026
-91.92% 93.20%
Unlock
2027
-8.35% 90.92%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -3.95 -0.96
35.14% 75.70%
P/E negative
EV/Sales negative

1 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast for earnings per share. The average Inovio Pharmaceuticals, Inc. EPS is

$-0.96
Unlock
. This is
75.88% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.96 75.88%
Unlock
, the lowest is
$-0.96 75.88%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-3.95 35.14%
2025
$-0.96 75.70%
Unlock
2026
$-0.55 42.71%
Unlock
2027
$-0.15 72.73%
Unlock

P/E ratio

Current -0.40 82.38%
2025
-1.66 315.00%
Unlock
2026
-2.89 74.10%
Unlock
2027
-10.60 266.78%
Unlock

Based on analysts' sales estimates for 2025, the Inovio Pharmaceuticals, Inc. stock is valued at an EV/Sales of

-9.33
Unlock
and an P/S ratio of
22.73
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -108.82 143.15%
2025
-9.33 91.42%
Unlock
2026
-1.11 88.12%
Unlock
2027
-0.37 66.68%
Unlock
2028
-0.15 60.60%
Unlock
2029
-0.08 46.87%
Unlock

P/S ratio

Current 265.00 32.19%
2025
22.73 91.42%
Unlock
2026
2.70 88.12%
Unlock
2027
0.90 66.68%
Unlock
2028
0.35 60.60%
Unlock
2029
0.19 46.88%
Unlock

Current Inovio Pharmaceuticals, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Mar 19 2025
RBC Capital
Locked
Locked
Locked Mar 19 2025
Citizens Capital Markets
Locked
Locked
Locked Mar 14 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 13 2025
JMP Securities
Locked
Locked
Locked Jan 10 2025
HC Wainwright & Co.
Locked
Locked
Locked Nov 18 2024
Oppenheimer
Locked
Locked
Locked Nov 18 2024
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 19 2025
Locked
RBC Capital:
Locked
Locked
Mar 19 2025
Locked
Citizens Capital Markets:
Locked
Locked
Mar 14 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 13 2025
Locked
JMP Securities:
Locked
Locked
Jan 10 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Nov 18 2024
Locked
Oppenheimer:
Locked
Locked
Nov 18 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today